DNA Drug Developer Seawolf Launches with $100 Million Funding and $1.2 Billion Sanofi Deal
San Diego-based Seawolf Therapeutics has emerged with $100 million in Series A funding and a deal with Sanofi worth up to $1.2 billion, aiming to develop DNA-based medicines that can be dosed repeatedly.
